Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph phase_2
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 2Efficacy & side effects
1(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (100.0%)

Trials by Status

active_not_recruiting150%
not_yet_recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
active_not_recruiting

Thymus Dosimetric and Morphologic Predictors of Radiation-Induced Lymphopenia in Stage III NSCLC

NCT07564089
not_yet_recruitingphase_2

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

NCT07314216

Clinical Trials (2)

Showing 2 of 2 trials
NCT07564089

Thymus Dosimetric and Morphologic Predictors of Radiation-Induced Lymphopenia in Stage III NSCLC

Active Not Recruiting
NCT07314216Phase 2

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

Not Yet Recruiting

All 2 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
2